EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open access · CC BY 4.0

Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma

Saskia Carstensen-Aurèche, Tobias Litzenburger, Dorothy De Sousa, Reinhard Sailer, Ewald Benediktus, Denis Delic, Fabian Müller, Meike Müller, Jens M Hohlfeld iD

British Journal of Pharmacology · 2026-06 · 183 (11) · 2660-2674

DOI: 10.1111/bph.70329 ↗

At a glance

Randomisierte kontrollierte Studie in British Journal of Pharmacology, published online on 2026-02-06. Written by Saskia Carstensen-Aurèche and 8 co-authors. Institution: Fraunhofer Institute of Toxicology and Experimental Medicine ITEM, Clinical Airway Research, Hannover, Germany. Major MEDLINE topics: Asthma, Syk Kinase, Protein Kinase Inhibitors, Anti-Asthmatic Agents. Cited 1 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: Boehringer Ingelheim Pharma GmbH & Co. KG.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma. Experimental Approach The single‐blinded, partially randomised, placebo‐controlled Phase I study evaluated single doses of BI 894416 (3–70 mg) in healthy volunteers. The single‐blinded, randomised, placebo‐controlled Phase Ib study in patients with mild asthma evaluated three single doses (75–170 mg) and four multiple doses (10–60 mg) of BI 894416 over an interval of 9 days. The primary objective of both studies was safety and tolerability, assessing the proportion of participants with drug‐related adverse events (AEs). Secondary endpoints related to pharmacokinetics and efficacy (Phase Ib study only). Key Results All except one randomised participant completed treatment (56 healthy volunteers and 68 mild asthmatics [29 received a single dose and 39 received multiple doses]). The most frequent drug‐related AEs were headache, diarrhoea and nausea (all of mild/moderate intensity). No serious AEs occurred. BI 894416 was rapidly absorbed with median time‐to‐peak concentration 0.5–1.0 h; exposure increased in a dose‐dependent manner. Basophils and nasal epithelial cells showed dose‐dependent modulation of activation‐ and disease‐associated genes and pathways. Conclusion and Implications BI 894416 was safe and well tolerated in healthy volunteers and mild asthmatics. Results from target engagement biomarkers demonstrated treatment‐ and dose‐dependent cellular modulation, potentially leading to decreased airway inflammation and airway obstruction.

Subjects

MeSH terms (MEDLINE)

AsthmaSyk KinaseProtein Kinase InhibitorsAnti-Asthmatic AgentsHumansAdultMaleFemaleMiddle AgedSingle-Blind MethodYoung AdultDose-Response Relationship, DrugAdolescentHealthy Volunteers

Author keywords

BI 894416CD63SYK inhibitorasthmabasophil activation test

Substances

Syk KinaseProtein Kinase InhibitorsSYK protein, humanAnti-Asthmatic Agents

Authors and institutions

  • Fraunhofer Institute of Toxicology and Experimental Medicine ITEM, Clinical Airway Research, Hannover, Germany.
  • German Center for Lung Research (DZL-BREATH), Hannover, Germany.
  • Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceutical Inc., Ridgefield, Connecticut, USA.
  • Department of Clinical Development & Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID profiles: Jens M Hohlfeld

Funding

  • Boehringer Ingelheim Pharma GmbH & Co. KG

Cite

APA

Carstensen-Aurèche, S., Litzenburger, T., De Sousa, D., Sailer, R., Benediktus, E., Delic, D., Müller, F., Müller, M., & Hohlfeld, J. M. (2026). Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma. British Journal of Pharmacology, 183(11), 2660-2674. https://doi.org/10.1111/bph.70329

Vancouver

Carstensen-Aurèche S, Litzenburger T, De Sousa D, Sailer R, Benediktus E, Delic D, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma. British Journal of Pharmacology. 2026;183(11):2660-2674. doi:10.1111/bph.70329

BibTeX
@article{CarstensenAurche2026,
  author = {Carstensen-Aurèche, Saskia and Litzenburger, Tobias and De Sousa, Dorothy and Sailer, Reinhard and Benediktus, Ewald and Delic, Denis and Müller, Fabian and Müller, Meike and Hohlfeld, Jens M},
  title = {Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {11},
  pages = {2660--2674},
  doi = {10.1111/bph.70329}
}
Start for free →